Patient safety and the next generation of HPV DNA tests

American Journal of Clinical Pathology

Volumn 134, Issue 2, 2010, Pages 193-199

  Kinney, Walter ^a   Stoler, Mark H ^b   Castle, Philip E ^c  

^a KAISER PERMANENTE   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cervical cancer; Cytology; HPV; HPV DNA testing; Human papillomavirus

Indexed keywords

VIRUS DNA;

CANCER DIAGNOSIS; CANCER SCREENING; CLINICAL ASSESSMENT; CYTOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; FOOD AND DRUG ADMINISTRATION; HUMAN; NOTE; OCCUPATION; PATIENT SAFETY; PRECANCER; PREVALENCE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; VIRUS INFECTION; WART VIRUS; CYTOCHEMISTRY; EARLY DIAGNOSIS; FEMALE; ISOLATION AND PURIFICATION; MASS SCREENING; METHODOLOGY; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTION; PRACTICE GUIDELINE; REVIEW; UTERINE CERVIX TUMOR; VIROLOGY;

DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; HISTOCYTOCHEMISTRY; HUMANS; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PRACTICE GUIDELINES AS TOPIC; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS;

EID: 77955591098     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPRI8XPQUEAA3K     Document Type: Note

References (41)

1. Wright TC Jr, Schiffman M, Solomon D, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol. 2004;103:304-309.
2. Stoler MH, Castle PE, Solomon D, et al. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am J Clin Pathol. 2007;127:335-337.
3. Meijer CJ, Berkhof J, Castle PE, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer. 2009;124:516-520.
4. Wright TC Jr, Massad LS, Dunton CJ, et al. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis. 2007;11:201-222.
5. Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357:1579-1588.
6. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst. 2008;100:492-501.
7. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med. 2009;360:1385-1394.
8. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing on the subsequent detection of cervical invasive and intraepithelial neoplasia [published online ahead of print January 18, 2010]. Lancet Oncol. 2010;11:249-257.
9. Carozzi FM, Del Mistro A, Confortini M, et al. Reproducibility of HPV DNA testing by Hybrid Capture 2 in a screening setting. Am J Clin Pathol. 2005;124:716-721.
10. Castle PE, Wheeler CM, Solomon D, et al. Interlaboratory reliability of Hybrid Capture 2. Am J Clin Pathol. 2004;122:238-245.
11. Castle PE, Solomon D, Wheeler CM, et al. Human papillomavirus genotype specificity of Hybrid Capture 2. J Clin Microbiol. 2008;46:2595-2604.
12. Kitchener HC, Almonte M, Thomson C, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol. 2009;10:672-682.
13. Sasieni P, Castle PE, Cuzick J. Further analysis of the ARTISTIC trial. Lancet Oncol. 2009;10:841-842.
14. Cervista HPV HR [package insert]. Madison, WI: Third Wave Technologies; 2008. http://www.accessdata.fda.gov/cdrh-docs/pdf8/P080014c.pdf. Accessed December 30, 2009.
15. Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet. 2007;370:890-907.
16. Castle PE, Fetterman B, Akhtar I, et al. Age-appropriate use of human papillomavirus vaccines in the US. Gynecol Oncol. 2009;114:365-369.
17. Datta SD, Koutsky LA, Ratelle S, et al. Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005. Ann Intern Med. 2008;148:493-500.
18. Castle PE, Fetterman B, Poitras N, et al. Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting. Obstet Gynecol. 2009;113:595-600.
19. de Sanjose S, Diaz M, Castellsague X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007;7:453-459.
20. Sherman ME, Lorincz AT, Scott DR, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst. 2003;95:46-52.
21. Kjaer S, Hogdall E, Frederiksen K, et al. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res. 2006;66:10630-10636.
22. World Health Organization. WHO HPV LabNet. http://www.who.int/ biologicals/areas/human-papillomavirus/WHO-HPV-LabNet/en/index.html. Accessed December 30, 2009.
23. Yabroff KR, Saraiya M, Meissner HI, et al. Specialty differences in primary care physician reports of Papanicolaou test screening practices: a national survey, 2006 to 2007. Ann Intern Med. 2009;151:602-611.
24. Jain N, Irwin K, Carlin L, et al. Use of DNA tests for human papillomavirus infection by US clinicians, 2004. J Infect Dis. 2007;196:76-81.
25. Irwin K, Montano D, Kasprzyk D, et al. Cervical cancer screening, abnormal cytology management, and counseling practices in the United States. Obstet Gynecol. 2006;108:397-409.
26. Castle PE, Katki HA. Benefits and risks of HPV testing in cervical cancer screening [letter]. Lancet Oncol. 2010;11:214-215.
27. Castle PE, Stoler MH, Solomon D, et al. The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report. Am J Clin Pathol. 2007;127:805-815.
28. Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA. 2001;285:1500-1505.
29. Carreon JD, Sherman ME, Guillen D, et al. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int J Gynecol Pathol. 2007;26:441-446.
30. Castle PE, Schiffman M, Wheeler CM, et al. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol. 2009;113:18-25.
31. Trimble CL, Piantadosi S, Gravitt P, et al. Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype. Clin Cancer Res. 2005;11:4717-4723.
32. Arbyn M, Kyrgiou M, Simoens C, et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ. 2008;337:a1284. doi:10.1136/bmj.a1284.
33. Cervista HPV 16/18 [package insert]. Madison, WI: Third Wave Technologies; 2008. http://www.accessdata.fda.gov/cdrh-docs/pdf8/P080015c.pdf. Accessed December 30, 2009.
34. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97:1072-1079.
35. Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119:1095-1101.
36. McCaffery K, Waller J, Forrest S, et al. Testing positive for human papillomavirus in routine cervical screening: examination of psychosocial impact. BJOG. 2004;111:1437-1443.
37. Waller J, Marlow LA, Wardle J. The association between knowledge of HPV and feelings of stigma, shame and anxiety. Sex Transm Infect. 2007;83:155-159.
38. Maggino T, Casadei D, Panontin E, et al. Impact of an HPV diagnosis on the quality of life in young women. Gynecol Oncol. 2007;107(1 suppl 1):S175-S179.
39. Kahn JA, Slap GB, Bernstein DI, et al. Personal meaning of human papillomavirus and Pap test results in adolescent and young adult women. Health Psychol. 2007;26:192-200.
40. Castle PE, Sideri M, Jeronimo J, et al. Risk assessment to guide the prevention of cervical cancer. J Low Genit Tract Dis. 2008;12:1-7.
41. Katki HA, Wacholder S, Solomon D, et al. Risk estimation for the next generation of prevention programmes for cervical cancer. Lancet Oncol. 2009;10:1022-1023.